

**DECLARATION and POWER OF ATTORNEY**

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**Pyrazolotriazines as CRF Antagonists**

the specification of which is attached hereto unless the following box is checked:

☐ was filed on \_\_\_\_\_ as U.S. Application No. \_\_\_\_\_ or PCT International Application No. \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Application No.	Country	Filing Date	Priority Claimed (Yes/No)
-----------------	---------	-------------	---------------------------

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States Provisional Application(s) listed below.

U.S. Provisional Application No.

U.S. Filing Date

60/128,008

April 6, 1999

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International Application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT International Application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application No.	U.S. Filing Date	Status (patented, pending or abandoned)
-----------------	------------------	---

**POWER OF ATTORNEY:** I hereby appoint the following attorney(s) and/or agent(s) the power to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Name:	Registration No.:
Blair Q. Ferguson	34,329
Gerald J. Boudreaux	35,073
Karen H. Kondrad	38,212
Scott K. Larsen	38,532
Maureen P. O'Brien	42,043
Norbert Reinert	18,926
Mary K. VanAtten	39,408
Kenneth B. Rubin	36,259
Rosemarie R. Wilk-Orescan	45,220

Send correspondence and direct

telephone calls to:

**Kenneth B. Rubin**

**DuPont Pharmaceuticals Company**  
c/o E. I. du Pont de Nemours and Co.  
Legal - Patents  
1007 Market Street  
Wilmington, DE 19898, U.S.A.

Tel. No.

**(302) 992-3215**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

**INVENTOR(S)**

Full Name of Inventor	Last Name	First Name	Middle Name
Signature (please sign full name): <i>Paul J. Gilligan</i>	<b>GILLIGAN</b>	<b>PAUL</b>	<b>J.</b>
Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	<b>WILMINGTON</b>	<b>DELAWARE</b>	<b>UNITED STATES</b>
Post Office Address	Post Office Address	City	State or Country
	<b>2629 PENNINGTON DRIVE</b>	<b>WILMINGTON</b>	<b>DELAWARE</b>
Full Name of Inventor	Last Name	First Name	Middle Name
Signature (please sign full name): <i>Richard A. Wilde</i>	<b>WILDE</b>	<b>RICHARD</b>	<b>G.</b>
Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	<b>NEWARK</b>	<b>DELAWARE</b>	<b>UNITED STATES</b>
Post Office Address	Post Office Address	City	State or Country
	<b>205 ROSEMAN COURT</b>	<b>NEWARK</b>	<b>DELAWARE</b>
			Zip Code
			<b>19810</b>
			<b>19711</b>

☐ Additional Inventors are being named on separately numbered sheets attached hereto.

**BEST AVAILABLE COPY**

**DOCKET NO.: PH-7094-B (BMS-2599)****PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of:

**Paul J. Gilligan****Richard G. Wilde**

Confirmation No.: Not yet assigned

Application No.: Not yet assigned

Group Art Unit: Not yet assigned

Filing Date: Not yet assigned

Examiner: Not yet assigned

For: **PYRAZOLOTRIAZINES AS CRF ANTAGONISTS**☒ MS Patent Application ☐ MS Design ☐ MS Sequence

Commissioner for Patents


P.O. Box 1450

Alexandria, VA 22313-1450

**ASSOCIATE POWER OF ATTORNEY**

The undersigned, of Bristol-Myers Squibb Pharma Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, Attorney(s) and/or Agents for Applicant(s), hereby appoints all attorneys and/or agents associated with Customer No. 23377 with full power to prosecute the above-identified application and to transact all business in the Patent Office connected therewith.

Please continue to direct all correspondence to Shah R. Makujina, Esq. at the correspondence address associated with Customer No.

**\*23914\*****23914****PATENT TRADEMARK OFFICE**Date: *March 18, 2004*Blair Q. Ferguson  
Registration No. 34,329

Woodcock Washburn LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

© ww

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Gilligan, et al.

Confirmation No.: 2310

Serial No: 09/990,138

Group Art Unit: 1624

Filed: November 21, 2001

Examiner: Ford, John M.

For: Pyrazolotriazines as CRF Antagonists

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

ASSOCIATE POWER OF ATTORNEY

The undersigned, of the BRISTOL MYERS SQUIBB COMPANY, Attorney(s) and/or Agents for Applicant(s), hereby appoints the following:


Richard E. Kurtz	Registration No. 19,263	Michael K. Jones	Registration No. 41,100
Dale M. Heist	Registration No. 28,425	Frank T. Carroll	Registration No. 42,392
John W. Caldwell	Registration No. 28,937	Thomas E. Watson	Registration No. 43,243
Gary H. Levin	Registration No. 28,734	Peter M. Ullman	Registration No. 43,963
Steven J. Rocci	Registration No. 30,489	Richard B. LeBlanc	Registration No. 39,495
Dianne B. Elderkin	Registration No. 28,598	Joseph D. Rossi	Registration No. 47,038
John P. Donohue, Jr.	Registration No. 29,916	George J. Awad	Registration No. 46,528
Henrik D. Parker	Registration No. 31,863	Steven D. Maslowski	Registration No. 46,905
Suzanne E. Miller	Registration No. 32,279	S. Maurice Valla	Registration No. 43,966
Lynn B. Morreale	Registration No. 32,842	Emma R. Dailey	Registration No. 48,491
Joseph Lucci	Registration No. 33,307	Vincent J. Roccia	Registration No. 43,887
Michael P. Dunnam	Registration No. 32,611	Stephen C. Timmins	Registration No. 48,481
Michael D. Stein	Registration No. 34,734	Richard D. Watkins	Registration No. 50,993
Albert J. Marcellino	Registration No. 34,664	Erich M. Falke	Registration No. 49,049
David R. Bailey	Registration No. 35,057	Jane E. Inglese	Registration No. 48,444
Barbara L. Mullin	Registration No. 38,250	Raymond N. Scott, Jr.	Registration No. 48,666
Kevin M. Flannery	Registration No. 35,871	David L. Marcus	Registration No. 46,897
David A. Cherry	Registration No. 35,099	Lawrence A. Aaronson	Registration No. 38,369
Lynn A. Malinoski	Registration No. 38,788	John A. Harrelson, Jr.	Registration No. 42,637
Steven B. Samuels	Registration No. 37,711	Joseph Milowic, III	Registration No. 52,034
Janet E. Reed	Registration No. 36,252	Kenneth R. Eiferman	Registration No. 51,647
Alfred W. Zaher	Registration No. 42,248	Karen M. Whitney	Registration No. P52,355
Robert B. Washburn	Registration No. 16,574	Amy Carr-Trexler	Registration No. 51,531
Norman L. Norris	Registration No. 24,196	Daniel D. Biesterveld	Registration No. 45,898
Michael J. Swope	Registration No. 38,041	Sharon Fenick	Registration No. 45,269
Michael J. Bonella	Registration No. 41,628	Phillip A. Singer	Registration No. 40,176
Harold H. Fullmer	Registration No. 42,560	Wendy A. Choi	Registration No. 36,697
John E. McGlynn	Registration No. 42,863	Felicity E. Groth	Registration No. 47,042
Jonathan M. Waldman	Registration No. 40,861	Jeffrey H. Rosedale	Registration No. 46,018
Chad Ziegler	Registration No. 44,273	Andrew T. Serafini	Registration No. 41,303
David N. Farsiou	Registration No. 44,104	Bruce D. George	Registration No. 43,631
Steven H. Meyer	Registration No. 37,189	Tara L. Rachinsky	Registration No. 47,875
Paul B. Milcetic	Registration No. 46,261	Scott E. Scioli	Registration No. 47,930
Joseph R. Condo	Registration No. 42,431	Andrew J. Hagerty	Registration No. 44,141

DOCKET NO.: BMS-0875 (PH-7094-A)

PATENT

assigned to Woodcock Washburn LLP, One Liberty Place - 46<sup>th</sup> Floor, Philadelphia, PA 19103, to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

Date: 3/3/2003



---

Jing S. Belfield  
Registration No. 45,914  
Agent of Record

Please continue to send all correspondence to:

Bristol-Myers Squibb Pharmaceutical Company  
P.O. Box 4000  
Princeton, New Jersey 08543-4000  
Telephone: (609) 252-3791  
Facsimile: (609) 252-4526